Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin
Integumen plc (AIM: SKIN) is pleased to announce a greater than 99% reduction of bacterial growth in preliminary results of four formulations, all of which include Cannabinoid (CBD) oils, on Labskin in a range of cosmetic and skin-care treatments.
STOER For Men with CBD’s kills 99% of antibiotic-resistant bacteria
Tests, which include formulations of STOER For Men, the skin care product range owned by Integumen, were carried out on bacteria common to human skin. The bacteria tested are known to be one of the leading causes of foreign body infections with resistance to some antibiotics. While these are preliminary tests, with further results to follow, it provides clear evidence that the addition of CBD to cosmetics and skin-care treatments can play a major role in lowering the incidence of skin diseases.
Update on announcement of 7th January 2019
The Company trading update of 7 January 2019 noted that Cellulac (9.35% owned by Integumen) had developed a low-cost hemp-derived CBD oil extraction process and was collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics.
CBD Market Size
Explosive growth in the hemp-derived CBD category that has grown from a market category that did not exist five years ago to $190 Million in sales in 2017, poised to have reached $1.0 Billion in 2018, is led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $1.9B market by 2022.
Gerard Brandon (CEO of Integumen plc) commented:
“I am delighted that collaboration processes, put in place by new management in H2 2018, have resulted in achieving such a great outcome in a very short period of time. This shows the extent and value of the technology and clinical expertise that exists within Integumen.
This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema.
As well as having an extension to the range of STOER For Men skin care products, Labskin will be offering the same test services to clients adding CBD to their skin-care and cosmetic range of products”
Laboratory grown human skin testing services. Specifically developed to host harmful bacteria on simulated human skin. It is the best testing platform for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which cannot currently be carried out in vivo (animal models) due to ethical constraints of testing harmful bacteria.
FY 2018 total revenue £502k increased 111% (FY 2017 : £238k);
FY 2018 revenue from continued operations £274k increased 294% (FY 2017 : £93k) following Labskin test kit sales move to full skin-care product test services;
FY 2018 EBITDA losses reduced by 12% to (£1.25m) (FY 2017: (£1.40m))
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials. Combined with human volunteers doubles number of skin tests possible saving time and money.
Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on extending digital services on top of existing Labskin physical services to rapidly grow the Labskin AI footprint.
Gerry Brandon, the Company’s CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd, on Monday 13th May 2019
Labskin STOER study demonstrates 54% increase in skin hydration in 24 hours Promotion of new skin cells leaving fresher looking skin Launch of New Animal-Free Labskin Dandruff Test Integumen today announces the completion of development and launch of a new dandruff...
Integumen announces acquisition of RinoCloud Ltd, an integrated scientific data management services company for £3m. Placement for £2.5m and £1m debt reduction